<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="t0005">
 <label>Table 1</label>
 <caption>
  <p>Clinical trials for evaluating preventive and therapeutic options against SARS-CoV-2 (up to March 29th 2020).</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Clinical trials</th>
    <th>Identifier</th>
    <th>Status</th>
    <th>country</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Tocilizumab in COVID-19 Pneumonia</td>
    <td>NCT04317092</td>
    <td>Recruiting</td>
    <td>Italy</td>
   </tr>
   <tr>
    <td>Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19</td>
    <td>NCT04315298</td>
    <td>Recruiting</td>
    <td>United States</td>
   </tr>
   <tr>
    <td>A Pilot Study of Sildenafil in COVID-19</td>
    <td>NCT04304313</td>
    <td>Recruiting</td>
    <td>China</td>
   </tr>
   <tr>
    <td>ACE Inhibitors, Angiotensin II Type-I Receptor Blockers, and Severity of COVID-19 (CODIV-ACE)</td>
    <td>NCT04318418</td>
    <td>Not yet recruiting</td>
    <td>Italy</td>
   </tr>
   <tr>
    <td>Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention (HCQ4COV19)</td>
    <td>NCT04304053</td>
    <td>Recruiting</td>
    <td>Spain</td>
   </tr>
   <tr>
    <td>The Use PUL-042 Inhalation Solution to Prevent COVID-19 in Adults Exposed to SARS-CoV-2</td>
    <td>NCT04313023</td>
    <td>Not yet recruiting</td>
    <td/>
   </tr>
   <tr>
    <td>The Use of Angiotensin-Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective?</td>
    <td>NCT04322786</td>
    <td>Not yet recruiting</td>
    <td/>
   </tr>
   <tr>
    <td>Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.</td>
    <td>NCT04290871</td>
    <td>Withdrawn</td>
    <td/>
   </tr>
   <tr>
    <td>Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalized Patients With COVID-19</td>
    <td>NCT04322396</td>
    <td>Not yet recruiting</td>
    <td/>
   </tr>
   <tr>
    <td>Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool</td>
    <td>NCT04274322</td>
    <td>Not yet recruiting</td>
    <td/>
   </tr>
   <tr>
    <td>Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI</td>
    <td>NCT04324073</td>
    <td>Not yet recruiting</td>
    <td>France</td>
   </tr>
   <tr>
    <td>Hydroxychloroquine Versus Placebo in Patients Presenting COVID-19 Infection and at Risk of Secondary Complication: a Prospective, Multicentre, Randomised, Double-blind Study</td>
    <td>NCT04325893</td>
    <td>Not yet recruiting</td>
    <td/>
   </tr>
   <tr>
    <td>Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients</td>
    <td>NCT04293887</td>
    <td>Not yet recruiting</td>
    <td/>
   </tr>
   <tr>
    <td>Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia</td>
    <td>NCT04275388</td>
    <td>Not yet recruiting</td>
    <td/>
   </tr>
   <tr>
    <td>Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2</td>
    <td>NCT04323527</td>
    <td>Recruiting</td>
    <td>Brazil</td>
   </tr>
   <tr>
    <td>Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection</td>
    <td>NCT04283461</td>
    <td>Recruiting</td>
    <td>United States</td>
   </tr>
   <tr>
    <td>Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)</td>
    <td>NCT04322682</td>
    <td>Recruiting</td>
    <td>Canada</td>
   </tr>
   <tr>
    <td>Tocilizumab for SARS-CoV2 Severe Pneumonitis</td>
    <td>NCT04315480</td>
    <td>Not yet recruiting</td>
    <td>Italy</td>
   </tr>
   <tr>
    <td>Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV</td>
    <td>NCT04252274</td>
    <td>Recruiting</td>
    <td>China</td>
   </tr>
   <tr>
    <td>Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection</td>
    <td>NCT04251871</td>
    <td>Recruiting</td>
    <td>China</td>
   </tr>
   <tr>
    <td>COVIDL1: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection</td>
    <td>NCT04326426</td>
    <td>Not yet recruiting</td>
    <td/>
   </tr>
   <tr>
    <td>Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19</td>
    <td>NCT04306393</td>
    <td>Recruiting</td>
    <td>United States</td>
   </tr>
   <tr>
    <td>Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections</td>
    <td>NCT03331445</td>
    <td>Active, not recruiting</td>
    <td>Canada</td>
   </tr>
   <tr>
    <td>NK Cells Treatment for Novel Coronavirus Pneumonia</td>
    <td>NCT04280224</td>
    <td>Recruiting</td>
    <td>China</td>
   </tr>
   <tr>
    <td>Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection</td>
    <td>NCT04261907</td>
    <td>Not yet recruiting</td>
    <td/>
   </tr>
   <tr>
    <td>A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia</td>
    <td>NCT04276987</td>
    <td>Not yet recruiting</td>
    <td/>
   </tr>
   <tr>
    <td>Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2</td>
    <td>NCT04308668</td>
    <td>Recruiting</td>
    <td>United States</td>
   </tr>
   <tr>
    <td>STOP PIV - Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects</td>
    <td>NCT03808922</td>
    <td>Recruiting</td>
    <td>United States</td>
   </tr>
   <tr>
    <td>Norwegian Coronavirus Disease 2019 Study</td>
    <td>NCT04316377</td>
    <td>Not yet recruiting</td>
    <td/>
   </tr>
   <tr>
    <td>Lessening Organ Dysfunction With VITamin C</td>
    <td>NCT03680274</td>
    <td>Recruiting</td>
    <td>Canada</td>
   </tr>
   <tr>
    <td>Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With Severe Acute Respiratory Failure</td>
    <td>NCT04244591</td>
    <td>Recruiting</td>
    <td>China</td>
   </tr>
   <tr>
    <td>Convalescent Plasma to Limit Coronavirus Associated Complications</td>
    <td>NCT04325672</td>
    <td>Not yet recruiting</td>
    <td>United States</td>
   </tr>
   <tr>
    <td>Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia</td>
    <td>NCT04264533</td>
    <td>Recruiting</td>
    <td>China</td>
   </tr>
   <tr>
    <td>Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure Drug: RoActemra iv, RoActemra sc, Kevzara sc</td>
    <td>NCT04322773</td>
    <td>Not yet recruiting</td>
    <td>Denmark</td>
   </tr>
   <tr>
    <td>Safety and Efficacy of Hydroxychloroquine Associated With Azythromycin in SARS-Cov-2 Virus</td>
    <td>NCT04322123</td>
    <td>Not yet recruiting</td>
    <td>Brazil</td>
   </tr>
   <tr>
    <td>Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)</td>
    <td>NCT04307693</td>
    <td>Recruiting</td>
    <td>Korea</td>
   </tr>
   <tr>
    <td>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</td>
    <td>NCT04292899</td>
    <td>Recruiting</td>
    <td>United States</td>
   </tr>
   <tr>
    <td>NestCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia (HOPE)</td>
    <td>NCT04315987</td>
    <td>Not yet recruiting</td>
    <td/>
   </tr>
   <tr>
    <td>Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT (BEST-RCT)</td>
    <td>NCT04305106</td>
    <td>Recruiting</td>
    <td>China</td>
   </tr>
   <tr>
    <td>The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia</td>
    <td>NCT04273529</td>
    <td>Not yet recruiting</td>
    <td/>
   </tr>
   <tr>
    <td>The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19</td>
    <td>NCT04273581</td>
    <td>Not yet recruiting</td>
    <td/>
   </tr>
   <tr>
    <td>Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells</td>
    <td>NCT04313322</td>
    <td>Recruiting</td>
    <td>Jordan</td>
   </tr>
   <tr>
    <td>Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial) (HYDRA)</td>
    <td>NCT04315896</td>
    <td>Not yet recruiting</td>
    <td/>
   </tr>
   <tr>
    <td>Tetrandrine Tablets Used in the Treatment of COVID-19 (TT-NPC)</td>
    <td>NCT04308317</td>
    <td>Enrolling by invitation</td>
    <td>China</td>
   </tr>
   <tr>
    <td>Fingolimod in COVID-19</td>
    <td>NCT04280588</td>
    <td>Recruiting</td>
    <td>China</td>
   </tr>
   <tr>
    <td>CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment (SAC-COVID)v</td>
    <td>NCT04317040</td>
    <td>Not yet recruiting</td>
    <td>United States</td>
   </tr>
   <tr>
    <td>Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19)</td>
    <td>NCT04288102</td>
    <td>Recruiting</td>
    <td>China</td>
   </tr>
   <tr>
    <td>The Clinical Study of Carrimycin on Treatment Patients With COVID-19</td>
    <td>NCT04286503</td>
    <td>Not yet recruiting</td>
    <td/>
   </tr>
   <tr>
    <td>Efficacy and Safety of Corticosteroids in COVID-19(Methylprednisolone)</td>
    <td>NCT04273321</td>
    <td>Recruiting</td>
    <td>China</td>
   </tr>
   <tr>
    <td>Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)</td>
    <td>NCT04318444</td>
    <td>Not yet recruiting</td>
    <td>United States</td>
   </tr>
   <tr>
    <td>Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial) (PHYDRA)</td>
    <td>NCT04318015</td>
    <td>Not yet recruiting</td>
    <td/>
   </tr>
   <tr>
    <td>Safety and Immunity of Covid-19 aAPC Vaccine</td>
    <td>NCT04299724</td>
    <td>Recruiting</td>
    <td>China</td>
   </tr>
   <tr>
    <td>Immunity and Safety of Covid-19 Synthetic Minigene Vaccine</td>
    <td>NCT04276896</td>
    <td>Recruiting</td>
    <td>China</td>
   </tr>
   <tr>
    <td>A Phase I Clinical Trial in 18–60 Adults (APICTH)(vaccine)</td>
    <td>NCT04313127</td>
    <td>Recruiting</td>
    <td>China</td>
   </tr>
   <tr>
    <td>Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019</td>
    <td>NCT04310228</td>
    <td>Recruiting</td>
    <td>China</td>
   </tr>
   <tr>
    <td>Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells</td>
    <td>NCT04302519</td>
    <td>Not yet recruiting</td>
    <td/>
   </tr>
   <tr>
    <td>Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)</td>
    <td>NCT04295551</td>
    <td>Not yet recruiting</td>
    <td/>
   </tr>
   <tr>
    <td>Chloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting (COPCOV)</td>
    <td>NCT04303507</td>
    <td>Not yet recruiting</td>
    <td/>
   </tr>
   <tr>
    <td>Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)</td>
    <td>NCT04273763</td>
    <td>Enrolling by invitation</td>
    <td>China</td>
   </tr>
   <tr>
    <td>Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19</td>
    <td>NCT04278963</td>
    <td>Active, not recruiting</td>
    <td>China</td>
   </tr>
   <tr>
    <td>Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Chloroquine for Treatment of COVID19: A Randomized Control Trial (THDMS-COVID19)</td>
    <td>NCT04303299</td>
    <td>Not yet recruiting</td>
    <td>Thailand</td>
   </tr>
   <tr>
    <td>The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19</td>
    <td>NCT04285190</td>
    <td>Not yet recruiting</td>
    <td/>
   </tr>
   <tr>
    <td>Immunoregulatory Therapy for 2019-nCoV: PD-1 blocking antibody + standard treatment, Thymosin + standard treatment, standard treatment</td>
    <td>NCT04268537</td>
    <td>Not yet recruiting</td>
    <td/>
   </tr>
   <tr>
    <td>Tocilizumab vs. CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19 (TACOS)</td>
    <td>NCT04306705</td>
    <td>Recruiting</td>
    <td>China</td>
   </tr>
   <tr>
    <td>Mild/Moderate 2019-nCoV Remdesivir RCT</td>
    <td>NCT04252664</td>
    <td>Recruiting</td>
    <td>China</td>
   </tr>
   <tr>
    <td>Losartan for Patients With COVID-19 Requiring Hospitalization</td>
    <td>NCT04312009</td>
    <td>Not yet recruiting</td>
    <td>United States</td>
   </tr>
   <tr>
    <td>Trial of Treatments for COVID-19 in Hospitalized Adults (DisCoVeRy)
     <break/>Drug: Remdesivir, Lopinavir/ritonavir, Interferon Beta-1A, Standard of care
    </td>
    <td>NCT04315948</td>
    <td>Not yet recruiting</td>
    <td/>
   </tr>
   <tr>
    <td>Losartan for Patients With COVID-19 Not Requiring Hospitalization</td>
    <td>NCT04311177</td>
    <td>Not yet recruiting</td>
    <td>United States</td>
   </tr>
   <tr>
    <td>Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia</td>
    <td>NCT04273646</td>
    <td>Not yet recruiting</td>
    <td>China</td>
   </tr>
   <tr>
    <td>Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus</td>
    <td>NCT04252118</td>
    <td>Recruiting</td>
    <td>China</td>
   </tr>
   <tr>
    <td>The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia</td>
    <td>NCT04261426</td>
    <td>Not yet recruiting</td>
    <td/>
   </tr>
   <tr>
    <td>A Prospective/Retrospective, Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia
     <break/>Drug: Abidol hydrochloride, Oseltamivir, Lopinavir/ritonavir
    </td>
    <td>NCT04255017</td>
    <td>recruiting</td>
    <td>China</td>
   </tr>
   <tr>
    <td>A Prospective/Retrospective, Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia
     <break/>Drug: Abidol hydrochloride, Abidol Hydrochloride combined with Interferon atomization
    </td>
    <td>NCT04254874</td>
    <td>recruiting</td>
    <td>China</td>
   </tr>
   <tr>
    <td>Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia (BEST-CP)</td>
    <td>NCT04275414</td>
    <td>recruiting</td>
    <td>China</td>
   </tr>
   <tr>
    <td>A Randomized, Open, Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia</td>
    <td>NCT04261270</td>
    <td>recruiting</td>
    <td>China</td>
   </tr>
   <tr>
    <td>Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress (COVID-AIV)</td>
    <td>NCT04311697</td>
    <td>Not yet recruiting</td>
    <td>Israel</td>
   </tr>
   <tr>
    <td>The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia
     <break/>Drug: Methylprednisolone
    </td>
    <td>NCT04263402</td>
    <td>recruiting</td>
    <td>China</td>
   </tr>
   <tr>
    <td>Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19 (NoCovid)</td>
    <td>NCT04305457</td>
    <td>Recruiting</td>
    <td>United States</td>
   </tr>
   <tr>
    <td>Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study. (BARI-COVID)</td>
    <td>NCT04320277</td>
    <td>Recruiting</td>
    <td>Italy</td>
   </tr>
   <tr>
    <td>Adaptive COVID-19 Treatment Trial (ACTT)
     <break/>Drug: Remdesivir
    </td>
    <td>NCT04280705</td>
    <td>Recruiting</td>
    <td>United States</td>
   </tr>
   <tr>
    <td>Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu
     <break/>Drug: N-acetylcysteine + Fuzheng Huayu Tablet, N-acetylcysteine + Placebo
    </td>
    <td>NCT04279197</td>
    <td>Recruiting</td>
    <td>China</td>
   </tr>
   <tr>
    <td>NO Prevention of COVID-19 for Healthcare Providers
     <break/>Drug: Inhaled nitric oxide gas
    </td>
    <td>NCT04312243</td>
    <td>Not yet recruiting</td>
    <td/>
   </tr>
   <tr>
    <td>Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients
     <break/>Drug: Immunoglobulin of cured patients, γ-Globulin
    </td>
    <td>NCT04264858</td>
    <td>Not yet recruiting</td>
    <td>China</td>
   </tr>
   <tr>
    <td>Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients
     <break/>Drug: Recombinant human interferon α1β
    </td>
    <td>NCT04293887</td>
    <td>Not yet recruiting</td>
    <td/>
   </tr>
   <tr>
    <td>Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff
     <break/>Drug: recombinant human Interferon Alpha-1b, thymosin alpha 1
    </td>
    <td>NCT04320238</td>
    <td>Recruiting</td>
    <td>China</td>
   </tr>
   <tr>
    <td>Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19</td>
    <td>NCT04292340</td>
    <td>Recruiting</td>
    <td>China</td>
   </tr>
   <tr>
    <td>Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus</td>
    <td>NCT04260594</td>
    <td>Not yet recruiting</td>
    <td/>
   </tr>
   <tr>
    <td>Evaluation of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of Novel Coronavirus Infection
     <break/>Drug: Ganovo + ritonavir+/-Interferon nebulization
    </td>
    <td>NCT04291729</td>
    <td>Completed</td>
    <td>China</td>
   </tr>
   <tr>
    <td>Eculizumab (Soliris) in Covid-19 Infected Patients</td>
    <td>NCT04288713</td>
    <td>Available</td>
    <td/>
   </tr>
   <tr>
    <td>Severe 2019-nCoV Remdesivir RCT</td>
    <td>NCT04257656</td>
    <td>Recruiting</td>
    <td>China</td>
   </tr>
   <tr>
    <td>nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19</td>
    <td>NCT04306393</td>
    <td>Recruiting</td>
    <td>United States</td>
   </tr>
   <tr>
    <td>Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(CoV) Pneumonia</td>
    <td>NCT04269525</td>
    <td>Recruiting</td>
    <td>China</td>
   </tr>
   <tr>
    <td>Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection</td>
    <td>NCT04261907</td>
    <td>Not yet recruiting</td>
    <td/>
   </tr>
   <tr>
    <td>Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia</td>
    <td>NCT04264533</td>
    <td>Recruiting</td>
    <td>China</td>
   </tr>
   <tr>
    <td>Expanded Access Remdesivir (RDV; GS-5734™)</td>
    <td>NCT04302766</td>
    <td>Available</td>
    <td/>
   </tr>
   <tr>
    <td>Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia</td>
    <td>NCT04275388</td>
    <td>Not yet recruiting</td>
    <td/>
   </tr>
   <tr>
    <td>Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) to Prevent SARS-CoV-2 Infection</td>
    <td>NCT04283461</td>
    <td>recruiting</td>
    <td>United States</td>
   </tr>
   <tr>
    <td>Tocilizumab for SARS-CoV2 Severe Pneumonitis</td>
    <td>NCT04315480</td>
    <td>Not yet recruiting</td>
    <td>Italy</td>
   </tr>
   <tr>
    <td>Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV</td>
    <td>NCT04252274</td>
    <td>recruiting</td>
    <td>China</td>
   </tr>
   <tr>
    <td>Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV (HC-nCoV)</td>
    <td>NCT04261517</td>
    <td>Completed</td>
    <td>China</td>
   </tr>
   <tr>
    <td>Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection
     <break/>Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules, Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)
    </td>
    <td>NCT04251871</td>
    <td>recruiting</td>
    <td>China</td>
   </tr>
   <tr>
    <td>Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia</td>
    <td>NCT04275245</td>
    <td>recruiting</td>
    <td>China</td>
   </tr>
   <tr>
    <td>Stem Cell Educator Therapy Treat the Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2</td>
    <td>NCT04299152</td>
    <td>Not yet recruiting</td>
    <td/>
   </tr>
   <tr>
    <td>NK Cells Treatment for Novel Coronavirus Pneumonia</td>
    <td>NCT04280224</td>
    <td>Recruiting</td>
    <td>China</td>
   </tr>
   <tr>
    <td>Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With Severe Acute Respiratory Failure
     <break/>Drug: methylprednisolone therapy
    </td>
    <td>NCT04244591</td>
    <td>Recruiting</td>
    <td>China</td>
   </tr>
   <tr>
    <td>Norwegian Coronavirus Disease 2019 Study
     <break/>Drug: Hydroxychloroquine Sulfate
    </td>
    <td>NCT04316377</td>
    <td>Not yet recruiting</td>
    <td/>
   </tr>
   <tr>
    <td>Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment</td>
    <td>NCT04276688</td>
    <td>Recruiting</td>
    <td>China</td>
   </tr>
   <tr>
    <td>Post-exposure Prophylaxis for SARS-Coronavirus-2 Drug: Hydroxychloroquine</td>
    <td>NCT04308668</td>
    <td>Recruiting</td>
    <td>United States</td>
   </tr>
   <tr>
    <td>A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia</td>
    <td>NCT04276987</td>
    <td>Not yet recruiting</td>
    <td/>
   </tr>
   <tr>
    <td>Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection</td>
    <td>NCT04290858</td>
    <td>Withdrawn</td>
    <td/>
   </tr>
   <tr>
    <td>Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.</td>
    <td>NCT04290871</td>
    <td>Withdrawn</td>
    <td/>
   </tr>
  </tbody>
 </table>
</table-wrap>
